Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 20/20 | 0.87 |
| ▸ | GIPR | P48546 | 11/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648190 | 0.93 | GCGR (1.00) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2648554 | 0.93 | GCGR (1.00) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2647099 | 0.92 | GCGR (0.92) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2648942 | 0.92 | GCGR (0.85) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2647170 | 0.90 | GCGR (0.83) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2647393 | 0.89 | GCGR (0.87) | GCGRGIPR | |
| SCHEMBL2648935 | 0.89 | GCGR (0.87) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2647086 | 0.88 | GCGR (0.85) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL6135453 | 0.88 | GCGR (0.84) | GCGRGIPR | |
| SCHEMBL2649019 | 0.87 | GCGR (0.76) | GCGRGIPRCYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256175-A1 | Novel glucagon antagonists/inverse agonists | LAU JESPER | 2005-11-17 | — | — | US | disclosed |
| US-6881746-B2 | Glucagon antagonists/inverse agonists | NOVO NORDICK A/S (DK) | 2005-04-19 | — | — | US | disclosed |
| EP-1519723-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2005-04-06 | — | — | EP | disclosed |
| US-20040014789-A1 | Novel glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2004-01-22 | — | — | US | disclosed |
| WO-2004002480-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002480-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014789-A1 | Novel glucagon antagonists/inverse agonists | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885CYP3A4 3727/4885 |
| US-20050256175-A1 | Novel glucagon antagonists/inverse agonists | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885CYP3A4 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.